Viatris is also focusing on expanding its presence in key therapeutic areas, such as dermatology, ophthalmology, and gastroenterology, which show potential for growth. With its strong portfolio of both generic and legacy drugs and a global reach of over 165 countries, Viatris is well-positioned for continued success in the pharmaceutical industry.
Bears say
Viatris is facing challenges with its fragmented portfolio and declining sales due to the loss of patent exclusivity for key drugs like Lipitor and Viagra. Additionally, its merger with Mylan has not resulted in significant cost savings or increased efficiency. The highly competitive generics market and potential delays or failures in the pipeline development of selatogrel could hinder their future growth.
Viatris (VTRS) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Viatris (VTRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Viatris (VTRS) a Buy based on their latest research and market trends.
According to 6 analysts, Viatris (VTRS) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Viatris (VTRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.